Treatment for adults with TK2 deficiency using Doxecitin and Doxribthymine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of Doxecitin and Doxribthymine in adult participants diagnosed with thymidine kinase 2 (TK2) deficiency. It is an open-label, single-arm study conducted at the Neuromuscular Unit of '12 de Octubre' Hospital in Madrid. Participants will receive a daily oral dose of the treatment, starting at 130 mg/kg/day and potentially increasing to 260 mg/kg/day based on tolerability. The study will also assess mitochondrial DNA levels in muscle and uroepithelial cells before and after treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent by the subject.
2. Subject must be greater than 18 years of age at time of consent.
3. Genetic diagnosis of TK2 deficiency
4. Subject should have evidence of a moderate to severe disease, with motor and or respiratory involvement, shown by one of the following:

   1. North Star Ambulatory Assessment Scale (NSAA) less than 30
   2. 6-minute walking test less than 450 meters
   3. Force Vital Capacity in the sitting position less than 70 percent or a drop in the decubitus position greater than 10 percent or need for mechanical ventilation.
   4. Disabling symptoms and evidence of motor and/or respiratory function progressive decline.
5. Female subjects must have no intention to become pregnant during the study. Female subjects who are of childbearing potential (that is, following menarche until at least 1 year post-menopausal if not anatomically and physiologically incapable of becoming pregnant) must agree and commit to the use of highly effective methods of birth control for the duration of the study and for 30 days after the end of the study, and be willing to have additional pregnancy tests conducted during the study. Acceptable methods are defined as those that result, alone or in combination, in a low failure rate (that is, less than 1 percent per year) when used consistently and correctly, such as surgical sterilization, an intrauterine device, or hormonal contraception in combination with a barrier method.
6. Male subjects with partners of childbearing potential must agree to use effective contraception methods during the study and for at least 90 days after the last dose of the study medication. Acceptable methods include the use of condoms combined with spermicidal foam/gel/film/cream/suppository.
7. Willingness to comply with the study protocol, including but not limited to, all study procedures, study visits, and study drug compliance.

Exclusion Criteria:

1. History of liver disease, or liver function test results (alanine aminotransferase \[ALT\], aspartate transaminase \[AST\], or total bilirubin) greater than or equal2 times (2X) the upper limit of normal. Patients with transaminases greater than 2 times (2X) can participate with the approval and monitoring of a doctor specializing in liver toxicity.
2. Participation in a previous trial of any investigational agent for primary mitochondrial disease within 1 year prior to informed consent, or use of any other investigational therapy within 30 days (or 3 half-lives, whichever is longer) prior to informed consent, or participation in other clinical studies, within 30 days prior to informed consent, which in the opinion of the study Sponsor, may potentially confound results from this study.
3. Pregnant (females 10.0 years old or older will have a pregnancy test at screening), or breastfeeding

Where it's running

• Hospital Universitario 12 de Octubre
  Madrid, Madrid, Spain Recruiting

Study contacts

• Principal investigator: Cristina D Domínguez González, Dra. — Hospital 12 de Octubre
• Study coordinator: Cristina Domínguez González, Dra.
• Email: cdgonzalez@salud.madrid.org
• Phone: +34 917792582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Measuring oxygen levels in muscle tissue using a nanosensor

  This study is testing a tiny sensor to see if it can accurately measure oxygen levels in the muscles of people with mitochondrial myopathy and healthy volunteers during exercise.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06819683

• Effects of passive exercise on mitochondrial diseases

  This study is testing how different types of exercise, including passive exercise, affect people with mitochondrial diseases compared to healthy individuals.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05569122

• Global registry for mitochondrial disorders

  This study is creating a global database for mitochondrial disorders to help understand these diseases better and improve future treatments for patients.

  Recruiting at 34 sites LMU Klinikum · Innsbruck and 33 other locations · NCT05554835

• Home-based personalized training and video consultations for mitochondrial myopathy patients

  This study tests whether a personalized training program and video consultations can help people with mitochondrial myopathy improve their health and quality of life.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes · NCT05346627

• Measuring oxygen levels in muscle for mitochondrial myopathy

  This study is testing a new device that measures oxygen levels in muscles during exercise to see if it can help understand how mitochondrial myopathy affects patients and improve future treatments.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT04086329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.